深圳惠泰医疗器械股份有限公司

Group 1 - The company has appointed a new financial officer, Gui Qihan, following the resignation of Dai Zhenhua, who will continue to serve as a director and secretary of the board [3][5][6] - The investment in Liliang Medical Technology Co., Ltd. amounts to RMB 5 million, with a post-investment shareholding of 4% [9][10] - The overall pre-investment valuation of Liliang Medical is set at RMB 110 million, and the investment is part of a joint venture with related parties [14][23] Group 2 - The company has utilized RMB 1,097,822,585.78 of the raised funds as of June 30, 2025, leaving a balance of RMB 59,692,123.63 [28] - The company has established a management system for the raised funds to ensure compliance with relevant regulations [29] - The company has engaged in cash management with idle raised funds, achieving a net income of RMB 227,200 [35] Group 3 - The company has invested RMB 33,816.99 million of the raised funds into the regional headquarters project [37] - The company has not encountered any significant changes in project feasibility or delays in planned progress during the reporting period [40] - The company has complied with disclosure obligations regarding the use of raised funds, ensuring transparency and accuracy [44]